Imagine a world where a simple shot could shield the tiniest among us from a potentially devastating virus. That's the promise of monoclonal antibodies in the fight against Respiratory Syncytial Virus (RSV), a common yet often underestimated respiratory threat. While RSV typically presents as a mild cold in most people, it can morph into a serious illness for infants under six months and older adults, leading to complications like bronchiolitis, pneumonia, and even sepsis. But here's where it gets groundbreaking: recent advancements in immunization are changing the game, offering a shield of protection for these vulnerable populations.
Since 2022, the European Union has authorized innovative immunization products to combat RSV in infants and older adults. These include long-acting monoclonal antibodies administered to newborns during the winter season and vaccines for pregnant individuals to safeguard their babies during their first winter after birth. The RSV season in Europe, now back to its pre-pandemic pattern, stretches from October to April, making these interventions timely and crucial.
And this is the part most people miss: a rapid communication published in Eurosurveillance by Savulescu et al. analyzed data from three European countries with RSV immunization programs during the 2024–25 winter season. Their focus? The effectiveness of nirsevimab, a long-acting monoclonal antibody, in preventing RSV infections. The study screened data from 4,102 hospitalized children under two years old in Belgium, Portugal, and Spain, with 791 RSV-positive cases and 1,410 RSV-negative controls. Children were considered immunized if they received nirsevimab before testing, regardless of dose, age, or weight.
The findings are nothing short of remarkable. Immunization with nirsevimab demonstrated a pooled overall effectiveness of 79% in preventing RSV-related hospitalizations among 2,201 children. For infants aged 0–6 months—the group at highest risk for severe RSV illness—the effectiveness was a robust 80%. But here's the catch: protection isn’t permanent. It starts at 85% in the first month after immunization, drops to 78% between days 30 to 89, and further declines to 69% after three months. This underscores the need for ongoing monitoring of immunization effectiveness in future seasons.
Now, here’s where it gets controversial: While monoclonal antibodies show immense promise, their declining efficacy over time raises questions about the optimal timing and frequency of doses. Should we administer booster shots? How do we balance cost and accessibility? These are the debates shaping the future of RSV prevention. What’s your take? Do you think monoclonal antibodies are a game-changer, or is there more work to be done? Share your thoughts in the comments below.
For more details, dive into the full study: Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged <24 months and hospitalized for severe acute respiratory infection, European pilot study, 2024 to 2025, published in Eurosurveillance (2025). DOI: 10.2807/1560-7917.ES.2025.30.45.2500816.
Provided by the European Centre for Disease Prevention and Control (ECDC). This content is for informational purposes only and is subject to copyright. Reproduction without permission is prohibited.
